Last reviewed · How we verify

NCT07091526

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

Recruiting now Last updated 19 December 2025
What this trial tests

trial testing serum uric acid test in Serum Uric Acid in 168 participants. Currently enrolling.

Timeline
29 July 2025
Primary endpoint
29 December 2026
29 December 2026

Quick facts

Lead sponsorHepatopancreatobiliary Surgery Institute of Gansu Province
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment168
Start date29 July 2025
Primary completion29 December 2026
Estimated completion29 December 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Who can join

Adults 18 to 85, any sex, with Serum Uric Acid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Hepatopancreatobiliary Surgery Institute of Gansu Province trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07091526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing